Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy — ASPIRATE  

Acute Mountain Sickness Clinical Trial

Official title: Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

Status Completed

Clinical Trial Summary

This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.

Clinical Trial Description

The specific aim of this study is to evaluate if acetazolamide will be similar to ibuprofen (i.e. Ibuprofen being non-inferior) in decreasing the incidence of Acute Mountain Sickness (AMS) in travelers to high altitude. It has been shown that ibuprofen taken 3 times a day 6 hours prior to ascent is effective for the prevention of AMS, with a number needed to treat of 4, decreasing the odds of getting AMS by a third. The efficacy appears to be similar to acetazolamide, with a NNT of 3 -8, although these two medications have not been directly compared in prevention of AMS. Acetazolamide is diuretic that is the only FDA approved AMS prophylactic medication and the most commonly used drug for AMS prevention. Although acetazolamide has been given a 1A indication, it has been shown to limit exercise capabilities at high altitude, and rapid ascent has been shown to attenuate its protective effects. Ibuprofen has been given a IIB recommendation by the Wilderness Medical Society Practice Guidelines, in part because it has not directly compared to acetazolamide. It is unknown if a non-steroidal anti-inflammatory can provide protection from AMS equivalent to acetazolamide. ;

Related Conditions & MeSH terms

• Acute Mountain Sickness
• Altitude Sickness

• NCT number: NCT03154645
• Study type: Interventional
• Source: Stanford University
• Status: Completed
• Phase: Phase 1
• Start date: August 12, 2017
• Completion date: October 1, 2017